Why is Integra LifeSciences stock tumbling today?

Integra LifeSciences (IART) shares fell 16.2% to $13.49 after lowering its 2026 revenue and EPS guidance due to flooding damage at a key facility. The company expects $7M in Q3 revenue loss and $15M-$20M in Q4. It also announced a $600M debt refinancing. The stock dropped despite a positive U.S. market day.

Original reporting
Published Oct 2, 2026, 2:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 2:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The combined guidance cut and debt raise created a sharp sell‑off, despite a broadly positive market backdrop.

02

Market read

Integra's stock fell 16.2% on guidance miss, contrasting with a rising S&P 500, highlighting a company‑specific risk.

03

What to watch

Potential upside from the $600 M senior secured loan could improve liquidity if market perceives it as a strategic refinancing.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences announced a flood‑related production hit at its Cincinnati facility and simultaneously launched a $600 M senior secured term loan.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences released preliminary Q3 results and cut full‑year 2026 revenue and EPS guidance, triggering a 16.2% drop in its stock.

Expected impact

likely continued downward pressure as investors price in lower revenue and earnings forecasts

Evidence & confidence

The guidance cut is material, the flood impact reduces capacity through Q4 2026, and the debt refinancing adds leverage concerns, all of which support further sell‑off.

Market effects

Medical‑technology sector may see broader risk‑off as supply‑chain disruptions raise concerns.

U.S. equities largely up, but Integra's drop stands out as a company‑specific outlier.

Limited; impact confined to Integra and its niche market.

Counterpoint

If insurance recoveries exceed expectations, the downside could be overstated.

Key entities

  • Stuart Essig

    CEO of Integra LifeSciences, cited flood impact on results.

  • Lea Knight

    CFO, described the purpose of the new senior secured loan.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.